Immunodeficiency Disorders in Veterinary Patients

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Immunodeficiency disorders in veterinary patients result from either inherited genetic defects (primary) or acquired insults (secondary), leading to an inadequate immune response against pathogens, neoplastic cells, or foreign material.
• Primary immunodeficiencies, such as Severe Combined Immunodeficiency (SCID) due to defects in cytokine receptor signaling (e.g., JAK3 mutations), typically manifest in young animals with recurrent infections and failure to thrive.
• Secondary immunodeficiencies are more common and arise from factors like malnutrition, infectious agents (e.g., retroviruses), neoplasia, or immunosuppressive drug administration, often presenting with atypical disease manifestations or poor therapeutic response.
• Diagnostic evaluation begins with a minimum database (CBC, biochemistry, urinalysis) and progresses to lymphocyte subset analysis via flow cytometry, serum immunoglobulin quantification, and functional assays to characterize the specific immune defect.
• Common complications include opportunistic infections (e.g., Blastocystis sp.), autoimmunity due to tolerance breakdown, and lymphoproliferative disorders, necessitating a comprehensive approach to diagnosis and management.
• Species-specific considerations are crucial, with feline patients requiring retroviral testing (FIV/FeLV), and production animals necessitating herd-level investigation of management and nutritional factors alongside individual assessment.

Immunodeficiency disorders represent a heterogeneous group of conditions in which the immune system fails to mount an adequate protective response against infectious agents, neoplastic cells, or other foreign material. These disorders may arise from genetic defects present at birth or from acquired insults that impair immune function later in life. This article provides a structured framework for understanding the mechanisms, classification, and diagnostic approach to immunodeficiency in veterinary patients, with emphasis on the pathophysiologic principles that guide clinical reasoning. It is written for veterinary students and practitioners who require a working knowledge of congenital and acquired immune failure across multiple species.

The clinical importance of recognizing immunodeficiency extends beyond the management of recurrent infections. Patients with defective immune responses may present with atypical disease manifestations, fail to respond to standard therapy, or develop complications such as autoimmunity and lymphoproliferative disorders. Understanding the distinction between primary and secondary immunodeficiencies informs diagnostic testing, prognostic counseling, and therapeutic decision-making. This article covers the conceptual foundation of immune system organization, the major categories of primary immunodeficiencies recognized in domestic animals, and the common acquired causes of immune dysfunction, while excluding detailed discussion of specific viral pathogens and treatment protocols.

At a Glance

Organization of the Immune System

The immune system operates through two interconnected arms: innate immunity and adaptive immunity. Innate immunity provides immediate, nonspecific defense through physical barriers, phagocytic cells, natural killer cells, complement proteins, and acute-phase reactants. Adaptive immunity develops more slowly and confers antigen-specific memory through the actions of T lymphocytes and B lymphocytes. T cells mediate cell-mediated immunity, including cytotoxic killing of infected cells and regulation of immune responses through helper and regulatory subsets. B cells produce antibodies that neutralize pathogens, opsonize bacteria, and activate complement.

Effective immune function requires coordinated interaction between these components. Antigen-presenting cells, particularly dendritic cells and macrophages, capture pathogens and present peptide fragments to T cells in the context of major histocompatibility complex molecules. This presentation triggers T cell activation, cytokine production, and differentiation into effector and memory populations. B cell activation requires T cell help for most protein antigens, leading to antibody class switching and affinity maturation. Disruption at any point in this cascade can produce clinically significant immunodeficiency.

The primary lymphoid organs, bone marrow and thymus, generate and educate immune cells. The bone marrow produces hematopoietic stem cells that give rise to all blood cell lineages, including B cells in most mammalian species. The thymus supports T cell development, including positive selection for self-major histocompatibility complex recognition and negative selection to eliminate strongly autoreactive cells. The transcription factor Aire drives expression of tissue-specific self-antigens in the thymic medulla, enabling deletion of autoreactive T cells during central tolerance induction. Defects in this process contribute to the autoimmunity observed in some primary immunodeficiencies, as demonstrated in monogenic disorders studied in both mice and humans Westerberg et al., breakdown of T cell tolerance in primary immunodeficiency.

Primary Immunodeficiencies

Primary immunodeficiencies result from inherited genetic mutations that impair immune development or function. These disorders are typically recognized in young animals, although some may present later in life depending on the severity of the defect and environmental pathogen exposure. The molecular characterization of these conditions has advanced substantially through the study of human patients and the generation of animal models that recapitulate the human disease phenotype.

Severe Combined Immunodeficiency

Severe combined immunodeficiency (SCID) represents the most profound form of primary immunodeficiency, characterized by absence of functional T cells and, depending on the genetic defect, variable loss of B cell and natural killer cell function. Affected animals present within the first weeks to months of life with recurrent infections, failure to thrive, and marked lymphopenia. The molecular basis of SCID involves defects in cytokine receptor signaling pathways essential for lymphocyte development. Janus kinase 3 (Jak3) mutations cause autosomal recessive SCID in humans by disrupting signaling through the common gamma chain, a receptor subunit shared by multiple interleukin receptors critical for lymphocyte survival and proliferation Pesu et al., Jak3 and severe combined immunodeficiency. Similar mechanisms operate in veterinary patients, with breed-specific mutations identified in several species.

Other Primary Immunodeficiencies

Beyond SCID, veterinary patients may present with selective immunoglobulin deficiencies, defects in phagocyte function, complement deficiencies, and disorders of innate immune signaling. These conditions produce characteriztic clinical syndromes that vary by species and specific genetic defect. The diagnosis of primary immunodeficiency requires a high index of suspicion in young animals with recurrent or unusual infections, particularly when littermates or related animals are similarly affected. Breed predisposition should prompt consideration of specific genetic testing where available.

Secondary Immunodeficiencies

Secondary immunodeficiencies arise from external factors that impair immune function in previously immunocompetent individuals. These acquired defects are far more common in clinical practice than primary immunodeficiencies and may result from infectious agents, malnutrition, metabolic disease, neoplasia, or iatrogenic causes such as immunosuppressive drug administration. The distinction between primary and secondary immunodeficiency is clinically important because secondary causes may be reversible with treatment of the underlying condition.

Infectious agents can suppress immune function through multiple mechanisms, including direct infection of immune cells, induction of regulatory pathways, and depletion of lymphocyte populations. Malnutrition impairs cell-mediated immunity, complement activity, and antibody production, with protein-energy malnutrition representing a major cause of secondary immunodeficiency worldwide. Endocrine disorders such as hyperadrenocorticism and diabetes mellitus alter immune function through glucocorticoid excess and impaired neutrophil activity, respectively. Neoplasia may suppress immunity through tumor-derived factors or as a consequence of cytotoxic chemotherapy.

The relationship between immunodeficiency and opportunistic infection is bidirectional. Immunocompromised patients are susceptible to infections with organizms of low intrinsic virulence, and these infections may further impair immune function. Enteric parasites such as Blastocystis sp. are frequently identified in immunocompromised human patients, and the zoonotic potential of this organizm raises questions about its role in veterinary patients with immune dysfunction Wawrzyniak et al., Blastocystis pathogenesis and diagnosis. Recognition of this interaction is essential for comprehensive patient management.

Diagnostic Approach to the Immunodeficient Patient

The diagnostic evaluation of suspected immunodeficiency begins with a thorough history and physical examination. Historical features that should raise suspicion include recurrent infections with the same or different organizms, infections with opportunistic pathogens, poor response to appropriate antimicrobial therapy, and infections at unusual sites. Physical examination may reveal evidence of chronic disease, including poor body condition, lymphadenopathy, or organomegaly.

Initial laboratory evaluation should include a complete blood count with manual differential to assess lymphocyte numbers and morphology, serum biochemistry profile, and urinalysis. Persistent lymphopenia in a young animal warrants further investigation. Serum protein electrophoresis can identify hypogammaglobulinemia, while immunoglobulin quantification by radial immunodiffusion or ELISA provides specific information about antibody classes. Flow cytometric analysis of lymphocyte subsets distinguishes T cell, B cell, and natural killer cell populations and is essential for characterizing many primary immunodeficiencies. Functional assays, including lymphocyte proliferation testing and neutrophil function studies, may be indicated based on the suspected defect.

The diagnostic approach must be tailored to the species and clinical context. Reference intervals for immunologic parameters vary among species, and age-related changes in lymphocyte populations occur in young animals. Consultation with veterinary clinical pathologists and immunologists is recommended for complex cases. Educational resources such as the Davis-Thompson Foundation veterinary pathology resources and the MSD Veterinary Manual professional edition provide additional guidance on diagnostic interpretation and disease recognition.

Applied Assessment and Monitoring in the Immunodeficient Patient

Initial Triage and Minimum Database

The first decision point in evaluating a suspected immunodeficient patient is distinguishing a primary immune defect from a secondary cause. Secondary immunodeficiencies vastly outnumber primary disorders in clinical practice, so the initial database should screen for the most common acquired causes first. A complete blood count with manual differential, serum biochemistry panel, and urinalysis provide the foundation. The clinician should specifically evaluate neutrophil count and morphology, lymphocyte count, globulin fractions, and urine protein loss.

Persistent neutropenia below the reference interval in a patient with recurrent bacterial infections warrants bone marrow evaluation. Lymphopenia with concurrent hypoalbuminemia and proteinuria suggests protein-losing nephropathy as the underlying mechanism. Panhypoproteinemia with gastrointestinal signs points toward protein-losing enteropathy. Serum electrophoresis helps distinguish a monoclonal gammopathy from a polyclonal increase, and low gamma globulins support humoral immunodeficiency.

Age of onset remains a critical discriminator. A young animal with recurrent infections since weaning, failure to thrive, and a family history of early death in littermates suggests a primary disorder. An adult or geriatric patient with a recent onset of recurrent infections more likely has an acquired cause, including retroviral infection, neoplasia, endocrinopathy, or drug-induced immunosuppression.

Lymphocyte Subset Analysis and Functional Testing

When the minimum database supports an immune defect, flow cytometric immunophenotyping provides the next level of resolution. CD4 and CD8 T cell counts, B cell numbers, and NK cell populations help classify the defect. Panlymphopenia with absent T and B cells supports severe combined immunodeficiency, while absent B cells with preserved T cells suggests a humoral defect. The molecular basis of severe combined immunodeficiency involves cytokine receptor signaling through Janus kinase 3, and mutations in this pathway produce autosomal recessive forms of the disease Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.

Immunoglobulin quantification by radial immunodiffusion or nephelometry measures IgG, IgM, and IgA. Selective IgA deficiency may present with recurrent mucosal infections, while panhypogammaglobulinemia indicates a broader B cell defect. Functional antibody testing, such as measuring vaccine titers before and after immunization, assesses the humoral response capacity. A failure to mount a fourfold increase in titer after vaccination supports humoral immunodeficiency.

Neutrophil function testing includes oxidative burst assays and chemotaxis studies. Chronic granulomatous disease, caused by defects in the NADPH oxidase complex, produces normal neutrophil counts but impaired intracellular killing. The nitroblue tetrazolium test or dihydrorhodamine flow cytometric assay detects defective oxidative burst. These tests require specialized laboratories and are typically reserved for patients with recurrent bacterial or fungal infections and normal neutrophil numbers.

Monitoring Parameters During Immunosuppressive Therapy

Patients receiving immunosuppressive drugs require structured monitoring to detect emerging immunodeficiency before opportunistic infection develops. The monitoring frequency depends on the drug, dose, and duration of therapy. Glucocorticoids at immunosuppressive doses warrant weekly or biweekly assessment during induction, with gradual extension of intervals as the dose is tapered.

The clinician should adjust monitoring intervals based on patient status. A patient with pre-existing renal disease receiving a calcineurin inhibitor requires more frequent renal assessment. A patient with diabetes mellitus receiving glucocorticoids needs blood glucose monitoring within days of therapy initiation. Species differences also matter. Cats are more sensitive to the bone marrow suppressive effects of azathioprine than dogs, and the feline patient requires more frequent hematologic monitoring.

Recognizing and Managing Opportunistic Infections

Opportunistic infections in immunodeficient patients often involve organizms of low intrinsic virulence. Blastocystis sp. is among the few enteric parasites with a prevalence exceeding 5% in the general population of industrialized countries, and infection risk is higher in immunocompromised individuals and those with close animal contact Blastocystis, an unrecognized parasite: an overview of pathogenesis and diagnosis. The presence of this organizm in an immunodeficient patient with diarrhea warrants treatment, whereas the same finding in an immunocompetent patient may not require intervention.

The diagnostic approach to suspected opportunistic infection should include cytology of affected tissues, aerobic and anaerobic bacterial culture, fungal culture, and molecular testing where available. Imaging findings may be atypical in immunodeficient patients because the inflammatory response is blunted. A neutropenic patient with pneumonia may have minimal radiographic changes despite severe disease. The clinician should maintain a low threshold for advanced imaging and invasive sampling.

Documentation and Longitudinal Care

Accurate documentation of the immunodeficient patient requires a structured record that captures the diagnostic basis, baseline values, and trends over time. The medical record should include the specific immune defect identified, the date of diagnosis, baseline immunoglobulin concentrations, lymphocyte subset counts, and the results of functional testing. Each monitoring visit should document current medications, doses, body weight, and relevant laboratory values.

The record should also note the patient's infection history, including the site, organizm, and treatment response for each episode. This longitudinal data helps identify patterns that may indicate progression of the immune defect or complications of therapy. For example, recurrent sinopulmonary infections with the same organizm may indicate inadequate humoral immunity, while a change to a different organizm class may signal a new defect.

Primary immunodeficiencies often present with autoimmunity in addition to infection susceptibility. The breakdown of T cell tolerance in monogenic immunodeficiencies provides insight into how a single gene defect can produce both immunodeficiency and autoimmunity Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency. The clinician should document any autoimmune manifestations, as these may require separate therapeutic consideration.

Species-Specific Considerations

The diagnostic approach varies by species. Feline patients with recurrent infections should be tested for feline immunodeficiency virus and feline leukemia virus before pursuing more specialized immune testing. Equine patients with failure of passive transfer require measurement of serum immunoglobulin G within the first 24 hours of life. Bovine patients with recurrent infections in a herd context warrant investigation of colostrum management practices and herd-level nutritional factors.

Production animal patients present unique constraints. Cost limitations may preclude advanced diagnostic testing, and the decision to treat versus cull depends on the production system and the value of the individual animal. International standards for animal health and trade-related disease control may apply to certain notifiable immunodeficiencies WOAH terrestrial animal health standards. The clinician should consult current regional requirements when managing production animals with suspected immunodeficiency.

The availability of specialized testing varies by region and practice setting. Point-of-care testing for retroviral infections is widely available, but flow cytometry and immunoglobulin quantification may require referral to a diagnostic laboratory. The clinician should establish a relationship with a reference laboratory that can provide the required testing and interpret results in the context of the species and clinical presentation.

Complications and Failure Modes

Immunodeficiency in veterinary patients follows predictable failure patterns. Recognizing these early separates effective management from progressive decline.

Failure to clear primary infection. The index infection persists despite appropriate therapy. Detection requires repeat cytology, culture, or molecular testing at the treatment endpoint instead of reliance on clinical impression alone. For retroviral infections, persistent antigenaemia or detectable proviral load confirms the expected course, but for bacterial or fungal infections, a positive test after a completed course signals inadequate host clearance and mandates reassessment of both drug choice and immune status.

Opportunistic invasion. Commensal organizms become tissue invaders. Candida overgrowth in the oral cavity or gastrointestinal tract, Malassezia dermatitis, and bacterial translocation across compromised mucosal barriers are common sentinel events. Detection depends on cytological examination of lesions and body fluids, not on empirical treatment. The presence of organizms that a competent immune system would contain should trigger an immediate search for an underlying cause.

Immune reconstitution phenomena. When immune function improves, whether through treatment of the underlying cause or withdrawal of immunosuppressive drugs, a paradoxical worsening of clinical signs can occur. This reflects renewed inflammatory responses to residual antigen. The distinction from treatment failure rests on temporal association with immune recovery, rising lymphocyte counts or immunoglobulin levels where measurable, and the absence of viable organizms on repeat testing.

Autoimmune breakthrough. Primary immunodeficiencies frequently coexist with autoimmunity because failed central and peripheral tolerance mechanisms share genetic and cellular pathways. As monogenic primary immunodeficiency disorders demonstrate, the same defect that impairs pathogen clearance can permit autoreactive T cell survival. Immune-mediated hemolytic anemia, thrombocytopenia, and polyarthritis in a patient with recurrent infections should raise suspicion of an underlying immunodeficiency instead of being treated in isolation.

Common Errors and Corrective Actions

Less experienced clinicians make characteriztic mistakes. The most consequential is treating the infection without investigating the host. A second episode of an unusual infection, an infection with an opportunistic organizm, or a failure to respond to standard therapy should trigger an immunodeficiency workup, not another course of antibiotics.

A related error is overinterpreting a single abnormal laboratory value. Lymphopenia has many causes including stress, glucocorticoid administration, and acute viral infection. Confirm the abnormality on a second sample before pursuing invasive diagnostics. Conversely, a normal lymphocyte count does not exclude immunodeficiency because functional defects can exist with preserved cell numbers.

Misreading the significance of serological results is common. A negative antibody test in a severely immunocompromised patient may reflect failure of humoral immunity instead of absence of infection. Paired acute and convalescent titres are unreliable when antibody production is impaired. Antigen detection or molecular testing is preferred in this population.

The corrective action for each error is the same: return to first principles. Define the organizm, define the host defect, and treat both. The MSD Veterinary Manual professional edition provides species-specific guidance on interpreting diagnostic tests in immunocompromised patients.

Limitations of Current Evidence

The evidence base for veterinary immunodeficiency is uneven. Feline immunodeficiency virus and feline leukemia virus are well characterized, but the feline immunodeficiency virus model has also informed human neurocognitive disease research, illustrating how veterinary and human medicine inform each other. Canine primary immunodeficiencies are described largely through case reports and small case series, and breed-specific prevalence data are often lacking.

Expert opinion differs on several practical points. The threshold for starting prophylactic antimicrobials in a patient with unexplained recurrent infections is not standardized. The role of immunoglobulin replacement therapy in veterinary patients remains experimental. The utility of immunostimulant drugs is contested, with limited controlled evidence to support their use.

The simian immunodeficiency virus macaque model has advanced understanding of lentiviral neuropathogenesis, but extrapolation from experimental models to clinical patients requires caution. Similarly, gene therapy for severe combined immunodeficiency has revealed risks of retroviral insertional mutagenesis, informing the risk-benefit calculus for any future veterinary applications, but these remain investigational.

Referral, Consultation, and Reporting

Referral is warranted when the diagnostic workup exceeds available capacity. Flow cytometry for lymphocyte subset analysis, functional assays for lymphocyte proliferation, and immunoglobulin quantitation often require commercial or academic laboratories. The Davis-Thompson Foundation veterinary pathology resources offer diagnostic pathology support and case-based teaching material that can assist in challenging cases.

Specialist consultation is appropriate when a patient fails to respond to first-line management, when a primary immunodeficiency is suspected, or when the differential diagnosis includes conditions requiring specialised testing. Veterinary immunologists, clinical pathologists, and internal medicine specialists can provide guidance on test selection and interpretation.

Regulatory reporting obligations vary by jurisdiction and by pathogen. Certain immunodeficiency-associated infections, particularly those with zoonotic potential or reportable disease status, may require notification of public health or veterinary authorities. The World Organization for Animal Health terrestrial animal health standards define international reporting requirements for listed diseases, and the American Veterinary Medical Association practice resources provide guidance on professional obligations. Clinicians should familiarise themselves with local requirements before encountering a reportable case.

Referral is also appropriate when the clinician has reached the limit of their expertise, when the owner requires a second opinion, or when the emotional weight of a chronic immunodeficient patient exceeds what the practice team can support. Timely referral serves the patient, the owner, and the referring clinician.

Frequently Asked Questions

How Do I Prioritize Testing When Advanced Immunology Panels Are Not Available or Affordable?

Start with a complete blood count and manual blood smear review, serum biochemistry, and urinalysis. These identify cytopenias, globulin abnormalities, and protein loss that direct further investigation. A persistent lymphopenia with normal corticosteroid and stress responses warrants flow cytometry if referral is possible. When flow cytometry is unavailable, serial total leukocyte counts and lymphocyte morphology on smears provide useful longitudinal data. For suspected primary immunodeficiency in young animals, request immunoglobulin quantification and lymphocyte proliferation assays through a commercial laboratory. The MSD Veterinary Manual offers species-specific guidance on interpreting basic hematologic findings in immunodeficient patients. Document the limitations of your testing approach clearly in the medical record so subsequent clinicians understand which compartments were not assessed.

What Minimum Infection Control Measures Should a General Practice Implement for an Immunodeficient Patient?

Isolate the patient in a separate ward area with dedicated equipment and footbaths. Use gloves, gowns, and shoe covers for all handling. Restrict visitor access and cohort nursing staff where possible. Clean the housing area daily with a hospital-grade disinfectant active against the suspected pathogens. Screen in-contact animals for subclinical infection before introducing them to the immunodeficient patient. For feline patients, confirm retroviral status before any elective procedure. The AVMA practice resources provide infection control checklists adaptable to companion animal practice. If hospitalization is unavoidable in a mixed-species facility, schedule the immunodeficient patient's procedures at the end of the day to reduce cross-contamination risk.

How Should I Counsel an Owner About Prognosis When a Primary Immunodeficiency Is Confirmed?

Explain that affected animals rarely survive to adulthood without intensive intervention. Describe the specific defect in plain terms, for example a failure of T cell development in severe combined immunodeficiency. Discuss the realistic options: sustained antimicrobial prophylaxis, strict indoor confinement, or humane euthanasia. For breeds with known inherited defects, mention that littermates may be carriers or affected and that the breeder should be informed. The Davis-Thompson Foundation case collections include examples of primary immunodeficiencies that can help owners visualize the disease course. Be direct about financial and emotional costs of long-term management. Offer a follow-up appointment to revisit the decision after the owner has had time to process the information.

When Should I Suspect a Secondary Immunodeficiency instead of a Primary One?

Suspect secondary causes when clinical signs begin in adulthood, when the patient has a concurrent disease known to suppress immunity, or when immunosuppressive drugs are part of the history. Malnutrition, endocrinopathies such as hyperadrenocorticism, and chronic viral infections all produce acquired defects. A young animal with recurrent infections from weaning age points toward a primary defect. The distinction matters for prognosis and therapy. Secondary immunodeficiencies often improve when the underlying cause is corrected, whereas primary defects are permanent. The WOAH terrestrial animal health standards address surveillance for infectious causes of immunosuppression in production animals, which can guide herd-level investigation when multiple animals are affected.

What Records Should I Keep for an Immunodeficient Patient on Long-Term Immunosuppressive Therapy?

Maintain a flow sheet documenting each visit's body weight, temperature, leukocyte count, and current drug doses. Record any infection episodes with culture results and antimicrobial susceptibility data. Note vaccine status and avoid modified-live products in severely immunocompromised patients. Keep a problem list that distinguishes active infections from drug-related adverse effects. Serial photographs of skin lesions or mucosal surfaces help track response to therapy. Document owner-reported observations such as appetite, activity, and respiratory effort at each visit. This longitudinal record supports dose adjustments and provides objective data for discussions about treatment continuation. The MSD Veterinary Manual includes monitoring parameters for common immunosuppressive protocols that can be adapted to your practice's record templates.

How Does the Diagnostic Approach Differ in Production Animals Compared with Companion Animals?

In production animals, investigate immunodeficiencies at the herd level instead of the individual level. Calculate morbidity and mortality rates across age cohorts. Review management factors including colostrum delivery, nutrition, stocking density, and vaccination protocols. Submit affected animals for necropsy with histopathology and culture. Consider inherited defects when multiple related animals in a single genetic line are affected. The WOAH terrestrial animal health standards outline reporting obligations for notifiable diseases that cause immunosuppression, which may apply depending on the region and species. Economic constraints usually limit advanced immunologic testing in production settings, so prioritize ruling out infectious and nutritional causes before pursuing a genetic diagnosis.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• Blastocystis, an unrecognized parasite: an overview of pathogenesis and diagnosis.. 2013.
• Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration.. 2016.
• Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.. 2005.
• Genotoxicity of retroviral integration in hematopoietic cells.. 2006.
• An SIV/macaque model targeted to study HIV-associated neurocognitive disorders.. 2018.
• Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency--lessons learned from monogenic disorders in mice and men.. 2008.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Decision Framework for Anticoagulant Therapy in Veterinary Patients
• Decision Framework for Antiemetic Therapy in Veterinary Patients
• Decision Framework for Choosing Antifungal Therapy in Veterinary Patients
• Decision Framework for Antihypertensive Therapy in Veterinary Patients
• Decision Framework for Antiviral Therapy in Veterinary Patients

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.